The American Medical Association (AMA) has approved new Category I CPT codes for Medtronic's Altaviva™ implantable tibial neuromodulation device and Symplicity Spyral™ renal denervation system. These devices treat urge urinary incontinence and uncontrolled hypertension, respectively, and the new codes, effective January 2028, reflect strong clinical evidence and physician adoption. The Altaviva™ device offers a minimally invasive, long-lasting treatment for urinary incontinence, while the Symplicity Spyral™ system provides a minimally invasive option for managing high blood pressure. These approvals support better reimbursement pathways and could enhance patient access to these innovative therapies.
Medtronic PLC shares are trading at USD 86.32 on Pluang, showing a slight decline of 0.88% as of Oct 02, 2026 03:12 WIB. The stock has a market cap of $110.38 billion and a dividend yield of 3.34%, with all current Pluang orders being buys.
Medtronic announced FDA clearance and CE Mark for its latest Affera Prism-2 Mapping Software and CE Mark for the PulseSelect ProxBox Adapter with Proximity Indicator software. These upgrades enhance cardiac ablation procedures by providing detailed 3...
Abbott Laboratories, Medtronic, and Becton Dickinson, three leading medical device companies, have each increased their dividends recently, continuing long streaks of annual raises—54 years for Abbott, 49 for Medtronic, and consistent growth for Bect...
